Severe hemorrhagic cystitis (HC) can sometimes be lifethreatening after stem cell transplantation (SCT). Its incidence ranges from 7 to 52%. 1 Early HC is now seldom observed because of hyperhydration, urine alkalization and the routine use of mesna, a uroprotective agent that inactivates acrolein, the toxic metabolite of cyclophosphamide. 2 Late-onset HC persists as a severe complication. Possible risk factors include grade II-IV acute graft-versus-hostdisease, use of busulfan and/or total-body irradiation in the conditioning regimen, older age at transplant and certain viruses (polyoma BK and JC viruses, adenoviruses type 1 and 11, cytomegalovirus) which can reactivate in immune deficiency conditions. 3 Medical management of severe HC is based on hyperhydration, bladder irrigation and transfusional support, and is frequently ineffective. Other therapeutic strategies used have included local instillation of prostaglandin, phenol, alum, formalin, estrogens, epidermal growth factor and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF). 4, 5 If a viral infection is detected, the administration of antiviral agents is indicated. 6 Hyperbaric oxygen therapy has been associated with a few successes. 7 Major surgical procedures such as open cystotomy with urinary diversion and cystectomy with or without the reconstruction of a neobladder have been used, but are associated with high morbidity and mortality. 8 Percutaneous arterial embolization has been proposed for hemorrhage of pelvic origin. Superselective embolization of vesical arteries has been used for the treatment of HC secondary to radiotherapy, tumors and trauma. 9 A 21-year-old woman underwent allogeneic SCT from her HLA-identical brother for ALL in first CR. Conditioning regimen consisted of oral busulfan 4 mg/kg daily for 4 days and cyclophosphamide 50 mg/kg daily for 4 days. Mesna was administered. GVHD prophylaxis comprised cyclosporine and steroids. On day þ 31, the patient developed urinary frequency and pain that progressed to frank hematuria that was sterile on bacterial culture. Hyperhydration, bladder irrigation and transfusional support were begun without response over 2 months. Clots in the balder were removed repeatedly by cystoscopy.
The urine and serum were positive for BK virus DNA by PCR. Adenovirus was absent. Cytomegalovirus reactivation was seen intermittently, requiring several cycles of therapy with ganciclovir. On days þ 110 and þ 131, cidofovir was administered (total dose 10 mg/kg) with no effect on HC. Intravesical GM-CSF instillation did not help. HC remained severe requiring 20 packed red cell units and seven platelets units per week (Figure 1 ). Figure 1 Transfusion requirements before and after embolization.
On day þ 140, a selective embolization of both superior vesical arteries was performed under local anesthesia. In order to localize the hypogastric arteries, a digital angiogram of the aorto-iliac segment was carried out by retrograde catheterization of the right femoral artery. Subsequently, selective catheterization of the hypogastric arteries with a standard catheter Cobra II 4 F (Radiofocus, Glidecath, Terumo Corporation, Japan) was performed to identify the vesical arteries. Massive hypervascularity of the bladder (specifically the trigonal region) was observed (Figure 2a) . Superselective catheterization of the superior vesical arteries was achieved; the right artery via the left femoral artery and vice versa. Both arteries were embolized with Embogold (1 ml, 500-700 mm, Biosphere Medical s.a., France). After the procedure, a second angiography showed significant decrease in the bladder vascularity (Figure 2b) . The other vesical arteries were not embolized in the first procedure to avoid permanent ischemic damages from a overly rapid occlusion of all vasculature. HC improved immediately, but not completely. After 38 days, a second embolization of the right vesical artery was performed, with complete resolution of HC. The patient is well and in complete remission 17 months later.
To our knowledge, only two previous cases of HC following SCT have been successfully treated by this technique. In the two reported cases, patients underwent single embolizations, which were performed at an earlier time after the appearance of the urinary symptoms (45 and 50 days later, respectively). 10 In our case, the hemorrhage was life-threatening, had been resistant to several lines of medical therapy, and required two consecutive embolizations of vesical arteries. Both procedures were tolerated well and no adverse effects were observed.
Our data suggest that superselective embolization of vesical arteries seems to be a safe and effective treatment for HC in selected SCT patients. 
